Technical analysis of Can-Fite BioPharma Ltd. (CANF): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders, and erectile dysfunction. Its primary drug candidate, Piclidenoson, has successfully advanced through Phase III clinical trials for psoriasis and completed Phase II trials for COVID-19.
Price Performance
| 1 month | -35.07% |
| 3 months | -24.83% |
| Year-to-date | -44.00% |
| 1 year | -82.77% |
| 3 years | -95.76% |
| 5 years | -99.36% |
52-Week Range
| 52-week High | $13.40 |
| 52-week Low | $2.16 |
| Avg Volume (90d) | 1.2M |
Technical Indicators
| SMA 50 | $3.10 |
| SMA 200 | $3.72 |
| Beta | -0.10 |
| 30-day Volatility (annualised) | 112.3% |
| Price vs SMA 50 | -27.8% |
| Price vs SMA 200 | -39.8% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $8.40 | |
| 2025-11 | $7.00 | -16.7% |
| 2025-12 | $4.00 | -42.9% |
| 2026-01 | $4.01 | +0.2% |
| 2026-02 | $4.75 | +18.5% |
| 2026-03 | $3.10 | -34.7% |
| 2026-04 | $3.19 | +2.9% |
| 2026-05 | $3.35 | +5.0% |
| 2026-06 | $2.97 | -11.3% |
| 2026-07 | $3.15 | +6.1% |
| 2026-08 | $3.18 | +1.0% |
| 2026-09 | $2.24 | -29.6% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $2.24 |
| Market Cap | $3M |
| Exchange | AMEX |
| Country | IL |
Valuation Ratios
| Price / Book | 0.46 |
| EV / EBITDA | 0.05 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 3.46 |